SCHEMBL5732406

SCHEMBL5732406

O=C(Nc1nc2c(Cl)cccc2s1)Nc1cccc(Cl)c1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.57
ACP1 P24666 1/20 0.56
MAPK1 P28482 4/20 0.55
TSHR P16473 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
MEN1 O00255 8/20 0.55
MAPT P10636 4/20 0.55
LMNA P02545 3/20 0.55
GAA P10253 2/20 0.55
ALDH1A1 P00352 2/20 0.55
PKM P14618 1/20 0.55
HPGD P15428 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
MAPK14 Q16539 2/20 0.53
RET P07949 1/20 0.53
FLT1 P17948 1/20 0.53
KDR P35968 1/20 0.53
SENP7 Q9BQF6 2/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4917544 0.86 ACP1 (0.56) KMT2AACP1MAPK1TSHRNPSR1
SCHEMBL4919064 0.85 RAB9A (0.54) KMT2AACP1MAPK1TSHRNPSR1
SCHEMBL6370026 0.83 NPC1 (0.61) KMT2AACP1MAPK1NPSR1MEN1
SCHEMBL4921080 0.80 RAB9A (0.57) KMT2AACP1MAPK1TSHRNPSR1
SCHEMBL30754208 0.80 DYRK1A (0.71) KMT2AACP1MAPK1TSHRNPSR1
SCHEMBL4919372 0.79 LCK (0.57) KMT2AACP1MAPK1TSHRNPSR1
SCHEMBL10710090 0.79 MEN1 (0.79) KMT2AMAPK1MEN1MAPTLMNA
SCHEMBL4919868 0.78 TRPV1 (0.57) KMT2AACP1MAPK1TSHRNPSR1
SCHEMBL4920964 0.78 KMT2A (0.57) KMT2AACP1MAPK1TSHRNPSR1
SCHEMBL4861743 0.78 GAA (0.62) KMT2AACP1MAPK1TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680431-A1 BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2006-07-19 EP claimed
US-20050130974-A1 Benzothiazole compositions and their use as ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-06-16 US claimed
WO-2005037845-A1 BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2005-04-28 WO claimed
US-20080039629-A1 Benzothniazole compositions and their use as ubiquition ligation inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2008-02-14 US disclosed
US-20080039629-A1 Benzothniazole compositions and their use as ubiquition ligation inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2008-02-14 US disclosed
US-20050130974-A1 Benzothiazole compositions and their use as ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-06-16 US disclosed
WO-2005037845-A1 BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130974-A1 Benzothiazole compositions and their use as ubiquitin ligase inhibitors UBQLN1, UBE2T, NEDD4 KMT2A 1419/4885ACP1 2816/4885MAPK1 2937/4885
US-20080039629-A1 Benzothniazole compositions and their use as ubiquition ligation inhibitors UBQLN1, NEDD4, UCHL5 KMT2A 1591/4885ACP1 1249/4885MAPK1 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.